GlassScriptPhysician profile
Jeffrey Monk
NPI 1477282747
$5,037.03
in general payments reported to CMS, 2019-2025
25 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.66 · 2023: $2,417 · 2024: $1,416 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,259 · Travel and Lodging: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.22 |
| Travel and Lodging | $763.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,251.76 | 2023-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,097.42 | 2023-2025 | Relistor |
| Nalu Medical, INC. | $1,065.77 | 2023-2024 | Nalu Neurostimulation System |
| Valinor Pharma, LLC | $352.14 | 2023-2025 | Movantik |
| Forte Bio-Pharma LLC | $152.70 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Scilex Pharmaceuticals INC. | $148.24 | 2023-2025 | Ztlido |
| Averitas Pharma INC. | $104.18 | 2025 | Qutenza |
| Zimmer Biomet Holdings, INC. | $101.30 | 2023 | Comprehensive |
| Boston Scientific Corporation | $97.65 | 2025 | Wavewriter Alpha Prime 16 |
| Ibsa Pharma INC. | $81.05 | 2023-2025 | Tirosint, Licart, Tirosint |
| Pfizer INC. | $67.08 | 2025 | |
| Abbvie INC. | $65.05 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $62.58 | 2023-2025 | Horizant, Horizant |
| Biogen, INC. | $55.51 | 2023 | Spinraza |
| Vertos Medical, INC. | $50.26 | 2023-2024 | Mild Device Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Protega Pharmaceutials INC | $41.76 | 2023-2024 | Roxybond |
| Impel Pharmaceuticals INC. | $40.53 | 2023 | Trudhesa |
| Almatica Pharma LLC | $34.62 | 2023 | Gralise |
| Ipsen Biopharmaceuticals, INC | $29.54 | 2024 | Dysport |
| Teva Pharmaceuticals USA, INC. | $29.03 | 2024 | Ajovy |
| Indivior INC. | $28.10 | 2025 | Sublocade |
| Merz Pharmaceuticals, LLC | $27.28 | 2023 | Xeomin |
| Foundation Fusion Solutions, LLC | $20.85 | 2025 | |
| Medtronic, INC. | $17.97 | 2024 | Intellis Adaptivestim |
| Glaxosmithkline, LLC. | $14.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Monk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.